| Catalog No. | Size | Price (USD) |
| 10698-RP01-100 | 100 µL | $147.96 |
| 10698-RP01-200 | 200 µL | $251.64 |
| 10698-RP01-400 | 400 µL | $355.32 |
General Information
| Product name | Anti-B7-1/CD80 Antibody, Rabbit Polyclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human B7-1/CD80 |
| Immunogen | Recombinant Human CD80 / B7-1 protein (Catalog#10698-H08H) |
| Preparation | Produced in rabbits immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; Catalog#10698-H08H; Met 1-Asn 242; NP_005182.1). Total IgG was purified by Protein A affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-B7 Antibody; Anti-B7-1 Antibody; Anti-B7.1 Antibody; Anti-BB1 Antibody; Anti-CD28LG Antibody; Anti-CD28LG1 Antibody; Anti-LAB7 Antibody
Background Information
| Full Name | CD80 molecule |
| Description | The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas. |
| Research Areas |
|
| Tags |
|
| References |
|
